

Michael H Weisman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/271841/publications.pdf>

Version: 2024-02-01

201
papers

20,530
citations

38742
50
h-index

10158
140
g-index

204
all docs

204
docs citations

204
times ranked

17189
citing authors

#	ARTICLE	IF	CITATIONS
1	Correspondence on “Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry”™. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e138-e138.	0.9	4
2	Incidence of Ankylosing Spondylitis Among Male and Female United States Army Personnel. <i>Arthritis Care and Research</i> , 2023, 75, 332-339.	3.4	7
3	Identifying trajectories of radiographic spinal disease in ankylosing spondylitis: a 15-year follow-up study of the PSOAS cohort. <i>Rheumatology</i> , 2022, 61, 2079-2087.	1.9	8
4	The Interplay Between COVID-19 and Spondyloarthritis or Its Treatment. <i>Journal of Rheumatology</i> , 2022, 49, 225-229.	2.0	9
5	Risk Factors for Spinal Structural Damage in a Chinese Cohort With Ankylosing Spondylitis. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e118-e124.	0.9	4
6	High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. <i>Rheumatology</i> , 2022, 61, 4335-4343.	1.9	6
7	Spondyloarthritis in inflammatory bowel disease cohorts: systematic literature review and critical appraisal of study designs. <i>RMD Open</i> , 2022, 8, e001777.	3.8	11
8	Does Gender Impact a Diagnosis of Ankylosing Spondylitis?. <i>ACR Open Rheumatology</i> , 2022, 4, 540-546.	2.1	3
9	A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1179-1191.	3.7	7
10	Chronic inflammatory back pain commencing late in life: a neglected concept. <i>Internal Medicine Journal</i> , 2022, 52, 485-487.	0.8	0
11	The Need for SPACE to Plan the Future for Spondyloarthritis. <i>Journal of Rheumatology</i> , 2022, 49, 341-342.	2.0	1
12	The Effect of HLA-B27 on Susceptibility and Severity of COVID-19. <i>Journal of Rheumatology</i> , 2021, 48, 621-622.	2.0	19
13	Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 154-161.	0.9	21
14	Foreword. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, xi-xii.	1.9	0
15	A Panel of Biomarkers Associates With Increased Risk for Cardiovascular Events in Women With Systemic Lupus Erythematosus. <i>ACR Open Rheumatology</i> , 2021, 3, 209-220.	2.1	14
16	Pulse dose steroid experience among hospitalized patients with systemic lupus erythematosus: a single-center feasibility study. <i>Clinical Rheumatology</i> , 2021, 40, 1317-1320.	2.2	0
17	Association of Lipid Mediators With Development of Future Incident Inflammatory Arthritis in an Anti-“Citruillated Protein Antibody”-Positive Population. <i>Arthritis and Rheumatology</i> , 2021, 73, 955-962.	5.6	10
18	Low levels of anti-cyclic citrullinated peptide (CCP) 3.1 associated with diseases other than rheumatoid arthritis. <i>Medicine (United States)</i> , 2021, 100, e25558.	1.0	2

#	ARTICLE	IF	CITATIONS
19	The arthritis connection to inflammatory bowel disease (IBD): why has it taken so long to understand it?. RMD Open, 2021, 7, e001558.	3.8	23
20	Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2021, 80, 1168-1174.	0.9	49
21	Pain in Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2021, 47, xi-xii.	1.9	0
22	Repeated Spinal Mobility Measures and Their Association With Radiographic Damage in Ankylosing Spondylitis. ACR Open Rheumatology, 2021, 3, 413-421.	2.1	0
23	HLA-B27 is associated with reduced disease activity in axial spondyloarthritis. Scientific Reports, 2021, 11, 12331.	3.3	7
24	Does hydroxychloroquine improve patient reported outcomes in patients with lupus?. Lupus, 2021, 30, 1790-1798.	1.6	1
25	Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. Lupus Science and Medicine, 2021, 8, e000522.	2.7	5
26	Prevalence of sacroiliitis among patients referred for hip MR arthrography. Skeletal Radiology, 2021, , 1.	2.0	3
27	Lupus. Rheumatic Disease Clinics of North America, 2021, 47, xiii-xiv.	1.9	0
28	Evaluating associations of joint swelling, joint stiffness and joint pain with physical activity in first-degree relatives of patients with rheumatoid arthritis: Studies of the Aetiology of Rheumatoid Arthritis (SERA), a prospective cohort study. BMJ Open, 2021, 11, e050883.	1.9	2
29	The Association of Tumor Necrosis Factor Inhibitor Use With Incident Hypertension in Ankylosing Spondylitis: Data From the PSOAS Cohort. Journal of Rheumatology, 2021, , jrheum.210332.	2.0	3
30	Five-Year Follow-Up of Coronary Microvascular Dysfunction and Coronary Artery Disease in Systemic Lupus Erythematosus: Results From a Community-Based Lupus Cohort. Arthritis Care and Research, 2020, 72, 882-887.	3.4	21
31	American Indians Have a Higher Risk of Sjögren's Syndrome and More Disease Activity Than European Americans and African Americans. Arthritis Care and Research, 2020, 72, 1049-1056.	3.4	14
32	A latent class based imputation method under Bayesian quantile regression framework using asymmetric Laplace distribution for longitudinal medication usage data with intermittent missing values. Journal of Biopharmaceutical Statistics, 2020, 30, 160-177.	0.8	2
33	Nonsteroidal Antiinflammatory Drug Use and Association With Incident Hypertension in Ankylosing Spondylitis. Arthritis Care and Research, 2020, 72, 1645-1652.	3.4	21
34	Perceived Stress and Inflammatory Arthritis: A Prospective Investigation in the Studies of the Etiologies of Rheumatoid Arthritis Cohort. Arthritis Care and Research, 2020, 72, 1766-1771.	3.4	21
35	Education and Professional Development in Rheumatology. Rheumatic Disease Clinics of North America, 2020, 46, xiii-xiv.	1.9	0
36	A review of non-immune mediated kidney disease in systemic lupus erythematosus: A hypothetical model of putative risk factors. Seminars in Arthritis and Rheumatism, 2020, 50, 463-472.	3.4	6

#	ARTICLE	IF	CITATIONS
37	Examining Treatment Decision-Making Among Patients With Axial Spondyloarthritis: Insights From a Conjoint Analysis Survey. <i>ACR Open Rheumatology</i> , 2020, 2, 391-400.	2.1	12
38	Coping profiles and health outcomes among individuals with systemic sclerosis: A latent profile analysis approach. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 231-236.	1.7	2
39	Spondyloarthritis evolution: what is in your history?. <i>Current Opinion in Rheumatology</i> , 2020, 32, 321-329.	4.3	10
40	Biologics, spondylitis and COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1663-1665.	0.9	25
41	Longitudinal associations between depressive symptoms and clinical factors in ankylosing spondylitis patients: analysis from an observational cohort. <i>Rheumatology International</i> , 2020, 40, 1053-1061.	3.0	8
42	The road to rheumatoid arthritis prevention: challenges and opportunities. <i>Clinical Rheumatology</i> , 2020, 39, 1379-1381.	2.2	6
43	The changing profile of ankylosing spondylitis in the biologic era. <i>Clinical Rheumatology</i> , 2020, 39, 2641-2651.	2.2	3
44	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1243-1249.	0.9	93
45	Foreword. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, xi.	1.9	0
46	Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives. <i>Arthritis and Rheumatology</i> , 2020, 72, 1067-1071.	5.6	13
47	Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 193-201.	0.9	59
48	Population-based estimates of humoral autoimmunity from the U.S. National Health and Nutrition Examination Surveys, 1960-2014. <i>PLoS ONE</i> , 2020, 15, e0226516.	2.5	15
49	Spondyloarthritis: The Changing Landscape—Are We There Yet?. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, xiii-xiv.	1.9	2
50	Insights From Twitter Conversations on Lupus and Reproductive Health: Protocol for a Content Analysis. <i>JMIR Research Protocols</i> , 2020, 9, e15623.	1.0	6
51	Chronic back pain in first-degree relatives (FDRs) of patients with ankylosing spondylitis: predictive value of HLA-B27 and persistence of inflammatory back pain over time. <i>RMD Open</i> , 2020, 6, e001418.	3.8	3
52	Foreword. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, xiii-xiv.	1.9	0
53	Prevalence and Associations of Avascular Necrosis of the Hip in a Large Well-characterized Cohort of Patients With Inflammatory Bowel Disease. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 45-49.	0.9	8
54	Patient Concerns and Perceptions Regarding Biologic Therapies in Ankylosing Spondylitis: Insights From a Large-Scale Survey of Social Media Platforms. <i>Arthritis Care and Research</i> , 2019, 71, 323-330.	3.4	25

#	ARTICLE	IF	CITATIONS
55	Technology and Big Data in Rheumatology. Rheumatic Disease Clinics of North America, 2019, 45, xiii-xiv.	1.9	0
56	Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals. Annals of the Rheumatic Diseases, 2019, 78, 1235-1241.	0.9	64
57	Anticyclic Citrullinated Peptide Antibodies 3.1 and Anti-CCP-IgA Are Associated with Increasing Age in Individuals Without Rheumatoid Arthritis. Journal of Rheumatology, 2019, 46, 1556-1559.	2.0	12
58	Hydroxychloroquine â€” How Much Is Too Much?. Journal of Rheumatology, 2019, 46, 340-342.	2.0	6
59	Cauda Equina Syndrome in Ankylosing Spondylitis: Challenges in Diagnosis, Management, and Pathogenesis. Journal of Rheumatology, 2019, 46, 1582-1588.	2.0	15
60	Latent autoimmunity across disease-specific boundaries in at-risk first-degree relatives of SLE and RA patients. EBioMedicine, 2019, 42, 76-85.	6.1	18
61	New-onset non-infectious pulmonary manifestations among patients with systemic lupus erythematosus in Sweden. Arthritis Research and Therapy, 2019, 21, 48.	3.5	9
62	THU0358â€¦DEVELOPMENT OF A SET OF ASAS QUALITY STANDARDS FOR ADULTS WITH AXIAL SPONDYLOARTHRITIS. , 2019, , .		0
63	Drivers of Satisfaction With Care for Patients With Lupus. ACR Open Rheumatology, 2019, 1, 649-656.	2.1	9
64	Controversies in Rheumatology. Rheumatic Disease Clinics of North America, 2019, 45, xiii-xiv.	1.9	0
65	Treat to Target in Rheumatic Diseases: Rationale and Results. Rheumatic Disease Clinics of North America, 2019, 45, ix-x.	1.9	0
66	Clinical features related to statinâ€¦associated muscle symptoms. Muscle and Nerve, 2019, 59, 537-543.	2.2	12
67	Best Practices and Challenges to the Practice of Rheumatologists. Rheumatic Disease Clinics of North America, 2019, 45, xiii-xiv.	1.9	0
68	HLA class I and II alleles in susceptibility to ankylosing spondylitis. Annals of the Rheumatic Diseases, 2019, 78, 66-73.	0.9	52
69	Sex Differences in Quality of Life in Patients With Systemic Lupus Erythematosus. Arthritis Care and Research, 2019, 71, 1647-1652.	3.4	21
70	A promising approach to targeting type 1 IFN in systemic lupus erythematosus. Journal of Clinical Investigation, 2019, 129, 958-961.	8.2	18
71	Interstitial lung abnormalities in patients with early rheumatoid arthritis: A pilot study evaluating prevalence and progression. European Journal of Rheumatology, 2019, 6, 193-198.	0.6	22
72	Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. Lupus Science and Medicine, 2018, 5, e000247.	2.7	16

#	ARTICLE	IF	CITATIONS
73	A plausibly causal functional lupus-associated risk variant in the STAT1&STAT4 locus. Human Molecular Genetics, 2018, 27, 2392-2404.	2.9	34
74	Causes and Predictors of Early Hospital Readmission in Systemic Lupus Erythematosus. Journal of Rheumatology, 2018, 45, 929-933.	2.0	9
75	US National Health and Nutrition Examination Survey Arthritis Initiatives, Methodologies and Data. Rheumatic Disease Clinics of North America, 2018, 44, 215-265.	1.9	15
76	Digestive and Hepatic Aspects of the Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2018, 44, xiii-xiv.	1.9	0
77	Antibody Responses to Citrullinated and Noncitrullinated Antigens in the Sputum of Subjects With Rheumatoid Arthritis and Subjects at Risk for Development of Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 516-527.	5.6	51
78	The Brave New World of Rheumatic Disease Research Today. Rheumatic Disease Clinics of North America, 2018, 44, xiii.	1.9	1
79	Role of psychosocial reserve capacity in anxiety and depression in patients with systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2018, 21, 850-858.	1.9	14
80	Opioid Analgesic Use in Patients with Ankylosing Spondylitis: An Analysis of the Prospective Study of Outcomes in an Ankylosing Spondylitis Cohort. Journal of Rheumatology, 2018, 45, 188-194.	2.0	20
81	Renal Involvement in Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2018, 44, xi.	1.9	0
82	Etiology unknown: Qualitative analysis of patient attributions of causality in scleroderma. Journal of Scleroderma and Related Disorders, 2018, 3, 182-188.	1.7	0
83	Rheumatic Diseases in Older Adults. Rheumatic Disease Clinics of North America, 2018, 44, xi-xii.	1.9	0
84	A multiple imputation method based on weighted quantile regression models for longitudinal censored biomarker data with missing values at early visits. BMC Medical Research Methodology, 2018, 18, 8.	3.1	11
85	Harmonization, data management, and statistical issues related to prospective multicenter studies in Ankylosing spondylitis (AS): Experience from the Prospective Study Of Ankylosing Spondylitis (PSOAS) cohort. Contemporary Clinical Trials Communications, 2018, 11, 127-135.	1.1	14
86	Serologic features of cohorts with variable genetic risk for systemic lupus erythematosus. Molecular Medicine, 2018, 24, 24.	4.4	12
87	Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. Human Molecular Genetics, 2018, 27, 3813-3824.	2.9	43
88	Trans-Ethnic Mapping of BANK1 Identifies Two Independent SLE-Risk Linkage Groups Enriched for Co-Transcriptional Splicing Marks. International Journal of Molecular Sciences, 2018, 19, 2331.	4.1	12
89	IL-16/miR-125a axis controls neutrophil recruitment in pristane-induced lung inflammation. JCI Insight, 2018, 3, .	5.0	34
90	Trends in Functional Disability and Determinants of Clinically Meaningful Change Over Time in Hispanic Patients With Rheumatoid Arthritis in the US. Arthritis Care and Research, 2017, 69, 294-298.	3.4	15

#	ARTICLE	IF	CITATIONS
91	A Randomized, Double-blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. Arthritis and Rheumatology, 2017, 69, 846-853.	5.6	131
92	A Randomized, Double-blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. Arthritis and Rheumatology, 2017, 69, 837-845.	5.6	271
93	Omega-3 fatty acids are associated with a lower prevalence of autoantibodies in shared epitope-positive subjects at risk for rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 147-152.	0.9	72
94	Anti-Citrullinated Protein Antibodies Are Associated With Neutrophil Extracellular Traps in the Sputum in Relatives of Rheumatoid Arthritis Patients. Arthritis and Rheumatology, 2017, 69, 1165-1175.	5.6	93
95	Editorial: The Effect of Ethnicity on Cardiovascular Outcomes in Systemic Lupus Erythematosus Is Perhaps Not a Paradox. Arthritis and Rheumatology, 2017, 69, 1707-1709.	5.6	1
96	Prevalence of resting-ECG abnormalities in systemic lupus erythematosus: a single-center experience. Clinical Rheumatology, 2017, 36, 1311-1316.	2.2	27
97	Reproductive Health. Rheumatic Disease Clinics of North America, 2017, 43, xi-xii.	1.9	0
98	Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2017, 76, 153-158.	0.9	40
99	MicroRNA-302d targets IRF9 to regulate the IFN-induced gene expression in SLE. Journal of Autoimmunity, 2017, 79, 105-111.	6.5	66
100	Relationship between the gut and the spine: a pilot study of first-degree relatives of patients with ankylosing spondylitis. RMD Open, 2017, 3, e000437.	3.8	1
101	Transancestral mapping and genetic load in systemic lupus erythematosus. Nature Communications, 2017, 8, 16021.	12.8	314
102	Brief Report: Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjögren's Syndrome. Arthritis and Rheumatology, 2017, 69, 2187-2192.	5.6	35
103	Ethnicity and disease severity in ankylosing spondylitis a cross-sectional analysis of three ethnic groups. Clinical Rheumatology, 2017, 36, 2359-2364.	2.2	35
104	Psychological Factors that Link Socioeconomic Status to Depression/Anxiety in Patients with Systemic Lupus Erythematosus. Journal of Clinical Psychology in Medical Settings, 2017, 24, 302-315.	1.4	25
105	Association of Antibodies to Citrullinated Protein Antigens with Blood Pressure in First-Degree Relatives of Rheumatoid Arthritis Patients: The Studies of the Etiology of Rheumatoid Arthritis. American Journal of Nephrology, 2017, 46, 481-487.	3.1	4
106	Strong viral associations with SLE among Filipinos. Lupus Science and Medicine, 2017, 4, e000214.	2.7	24
107	Neurologic Manifestations of Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2017, 43, xi.	1.9	0
108	Cadherin-11 Is a Cell Surface Marker Up-Regulated in Activated Pancreatic Stellate Cells and Is Involved in Pancreatic Cancer Cell Migration. American Journal of Pathology, 2017, 187, 146-155.	3.8	38

#	ARTICLE	IF	CITATIONS
109	Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features. <i>Arthritis and Rheumatology</i> , 2017, 69, 630-642.	5.6	56
110	Infection and Malignancy in Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, xi-xii.	1.9	0
111	Effect of Tobacco Smoking on The Clinical, Histopathological, and Serological Manifestations of Sjögren's Syndrome. <i>PLoS ONE</i> , 2017, 12, e0170249.	2.5	25
112	Identification of a Sjögren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons. <i>PLoS Genetics</i> , 2017, 13, e1006820.	3.5	60
113	A Case of Henoch-Schonlein Purpura Associated with Rotavirus Infection in an Elderly Asian Male and Review of the Literature. <i>American Journal of Case Reports</i> , 2017, 18, 136-142.	0.8	8
114	Genomics in Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, xiii-xiv.	1.9	0
115	X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2016, 68, 1290-1300.	5.6	114
116	Review: Enthesitis: New Insights Into Pathogenesis, Diagnostic Modalities, and Treatment. <i>Arthritis and Rheumatology</i> , 2016, 68, 312-322.	5.6	128
117	Infection, malignancy, switching, biosimilars, antibody formation, drug survival and withdrawal, and dose reduction. <i>Current Opinion in Rheumatology</i> , 2016, 28, 303-309.	4.3	3
118	Associations of Smoking and Age With Inflammatory Joint Signs Among Unaffected First-Degree Relatives of Rheumatoid Arthritis Patients: Results From Studies of the Etiology of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1828-1838.	5.6	46
119	Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome. <i>Clinical Immunology</i> , 2016, 168, 25-29.	3.2	68
120	Sjogren's Disease. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, xi-xii.	1.9	1
121	Imaging in Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, xiii.	1.9	0
122	Patient-Reported Outcomes in Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, xiii-xiv.	1.9	1
123	Brief Report: Patients With Primary Sjögren's Syndrome Who Are Positive for Autoantibodies to Tripartite Motif-Containing Protein 38 Show Greater Disease Severity. <i>Arthritis and Rheumatology</i> , 2016, 68, 724-729.	5.6	22
124	Previous diagnosis of Sjögren's Syndrome as rheumatoid arthritis or systemic lupus erythematosus. <i>Rheumatology</i> , 2016, 55, 1195-1201.	1.9	42
125	Corticosteroids. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, xiii.	1.9	2
126	Lower omega-3 fatty acids are associated with the presence of anti-cyclic citrullinated peptide autoantibodies in a population at risk for future rheumatoid arthritis: a nested case-control study. <i>Rheumatology</i> , 2016, 55, 367-376.	1.9	52

#	ARTICLE	IF	CITATIONS
127	Multidimensional Model of Disability and Role Functioning in Rheumatoid Arthritis. Arthritis Care and Research, 2015, 67, 1686-1692.	3.4	4
128	Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. Nature Communications, 2015, 6, 7146.	12.8	220
129	Chest pain in lupus patients: the emergency department experience. Clinical Rheumatology, 2015, 34, 1969-1973.	2.2	2
130	Monoclonal Antibodies, Systemic Lupus Erythematosus, and Pregnancy: Insights from an Open-label Study. Journal of Rheumatology, 2015, 42, 728-730.	2.0	8
131	ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients. Annals of the Rheumatic Diseases, 2015, 74, 1627-1629.	0.9	86
132	Systemic Sclerosis. Rheumatic Disease Clinics of North America, 2015, 41, xiii.	1.9	1
133	Psoriatic Arthritis. Rheumatic Disease Clinics of North America, 2015, 41, xi.	1.9	0
134	Treatment of systemic lupus erythematosus patients with the BAFF antagonist eceptibody blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Research and Therapy, 2015, 17, 215.	3.5	48
135	Prevalence of Chronic Axial Pain, Inflammatory Back Pain, and Spondyloarthritis in Diagnosed Psoriasis. Arthritis Care and Research, 2015, 67, 829-835.	3.4	22
136	Foreword. Rheumatic Disease Clinics of North America, 2015, 41, xi.	1.9	0
137	The role of methotrexate in psoriatic arthritis: what is the evidence?. Clinical and Experimental Rheumatology, 2015, 33, S94-7.	0.8	9
138	The Effect of Riloncept versus Placebo on Health-Related Quality of Life in Patients with Poorly Controlled Familial Mediterranean Fever. BioMed Research International, 2014, 2014, 1-8.	1.9	25
139	Gout and Crystal Arthropathies. Rheumatic Disease Clinics of North America, 2014, 40, xiii.	1.9	0
140	A Panel of Biomarkers Is Associated With Increased Risk of the Presence and Progression of Atherosclerosis in Women With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2014, 66, 130-139.	5.6	103
141	New Population-Based Reference Values for Spinal Mobility Measures Based on the 2009-2010 National Health and Nutrition Examination Survey. Arthritis and Rheumatology, 2014, 66, 2628-2637.	5.6	13
142	MICA, a gene contributing strong susceptibility to ankylosing spondylitis. Annals of the Rheumatic Diseases, 2014, 73, 1552-1557.	0.9	47
143	Foreword. Rheumatic Disease Clinics of North America, 2014, 40, xi.	1.9	0
144	Foreword. Rheumatic Disease Clinics of North America, 2014, 40, xiii.	1.9	1

#	ARTICLE	IF	CITATIONS
145	The Concept of Axial Spondyloarthritis: Joint Statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in Response to the US Food and Drug Administration's Comments and Concerns. Arthritis and Rheumatology, 2014, 66, 2649-2656.	5.6	81
146	Spine fractures in ankylosing spondylitis: A case report and review of imaging as well as predisposing factors to falls and fractures. Seminars in Arthritis and Rheumatism, 2014, 44, 20-24.	3.4	14
147	The Impact of Tumor Necrosis Factor \pm Inhibitors on Radiographic Progression in Ankylosing Spondylitis. Arthritis and Rheumatism, 2013, 65, 2645-2654.	6.7	391
148	Performance of Anti- α -Cyclic Citrullinated Peptide Assays Differs in Subjects at Increased Risk of Rheumatoid Arthritis and Subjects With Established Disease. Arthritis and Rheumatism, 2013, 65, 2243-2252.	6.7	64
149	Foreword. Rheumatic Disease Clinics of North America, 2013, 39, xv.	1.9	0
150	Foreword. Rheumatic Disease Clinics of North America, 2013, 39, ix.	1.9	0
151	Foreword. Rheumatic Disease Clinics of North America, 2013, 39, xiii.	1.9	0
152	The prevalence of inflammatory back pain: population-based estimates from the US National Health and Nutrition Examination Survey, 2009-10. Annals of the Rheumatic Diseases, 2013, 72, 369-373.	0.9	79
153	Sputum Autoantibodies in Patients With Established Rheumatoid Arthritis and Subjects at Risk of Future Clinically Apparent Disease. Arthritis and Rheumatism, 2013, 65, 2545-2554.	6.7	160
154	Microvascular Angina: An Underappreciated Cause of SLE Chest Pain. Journal of Rheumatology, 2013, 40, 746-747.	2.0	10
155	Functional Limitations Due to Axial and Peripheral Joint Impairments in Patients With Ankylosing Spondylitis: Are Focused Measures More Informative?. Arthritis Care and Research, 2013, 65, 607-614.	3.4	9
156	The Epidemiology of Back Pain, Axial Spondyloarthritis and HLA-B27 in the United States. American Journal of the Medical Sciences, 2013, 345, 431-436.	1.1	149
157	Lung abnormalities in subjects with elevations of rheumatoid arthritis-related autoantibodies without arthritis by examination and imaging suggest the lung is an early and perhaps initiating site of inflammation in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2012, 71, A25.1-A25.	0.9	5
158	Foreword. Rheumatic Disease Clinics of North America, 2012, 38, ix-x.	1.9	0
159	Inflammatory Back Pain. Rheumatic Disease Clinics of North America, 2012, 38, 501-512.	1.9	36
160	Foreword. Rheumatic Disease Clinics of North America, 2012, 38, xiii-xv.	1.9	0
161	Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study. Arthritis Research and Therapy, 2012, 14, R261.	3.5	44
162	Prevalence of axial spondylarthritis in the United States: Estimates from a cross-sectional survey. Arthritis Care and Research, 2012, 64, 905-910.	3.4	183

#	ARTICLE	IF	CITATIONS
163	Brief Report: Airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: Early injury or initiating site of autoimmunity?. <i>Arthritis and Rheumatism</i> , 2012, 64, 1756-1761.	6.7	213
164	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 2677-2686.	6.7	3,838
165	Myocardial Ischemia in the Absence of Obstructive Coronary Artery Disease in Systemic Lupus Erythematosus. <i>JACC: Cardiovascular Imaging</i> , 2011, 4, 27-33.	5.3	138
166	High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1619-1624.	0.9	128
167	Development and validation of a case ascertainment tool for ankylosing spondylitis. <i>Arthritis Care and Research</i> , 2010, 62, 19-27.	3.4	23
168	Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. <i>Nature Genetics</i> , 2010, 42, 123-127.	21.4	573
169	Current Controversies in Spondyloarthritis: SPARTAN. <i>Journal of Rheumatology</i> , 2010, 37, 2617-2623.	2.0	11
170	Psychological Correlates of Self-reported Disease Activity in Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2010, 37, 829-834.	2.0	36
171	Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009, 60, 2428-2437.	6.7	178
172	A prospective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using first-degree relatives of probands with RA. <i>Arthritis and Rheumatism</i> , 2009, 61, 1735-1742.	6.7	129
173	Psychological correlates of self-reported functional limitation in patients with ankylosing spondylitis. <i>Arthritis Research and Therapy</i> , 2009, 11, R182.	3.5	51
174	Cost-Effectiveness of Sequential Therapy with Tumor Necrosis Factor Antagonists in Early Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 16-26.	2.0	38
175	Occupational physical activities and long-term functional and radiographic outcomes in patients with ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2008, 59, 822-832.	6.7	72
176	Do all drugs and treatments for rheumatoid arthritis have the same efficacy?. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 298-299.	3.2	2
177	Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 633-638.	0.9	225
178	A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. <i>Rheumatology</i> , 2007, 46, 1122-1125.	1.9	57
179	Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. <i>Nature Genetics</i> , 2007, 39, 1329-1337.	21.4	1,298
180	Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 607-612.	6.7	148

#	ARTICLE	IF	CITATIONS
181	Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2006, 33, 2162-6.	2.0	71
182	Chronic Inflammatory Demyelinating Polyneuropathy in Patients with Systemic Lupus Erythematosus: Prognosis and Outcome. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 175-184.	3.4	62
183	Progress toward the cure of rheumatoid arthritis? The best study. <i>Arthritis and Rheumatism</i> , 2005, 52, 3326-3332.	6.7	24
184	Relationships of Positive and Negative Affect to Coping and Functional Outcomes in Systemic Sclerosis. <i>Cognitive Therapy and Research</i> , 2004, 28, 593-610.	1.9	14
185	Development and validation of Cedars-Sinai Health-Related Quality of Life in Rheumatoid Arthritis (CSHQ-RA) short form instrument. <i>Arthritis and Rheumatism</i> , 2004, 51, 358-364.	6.7	8
186	Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. <i>Arthritis and Rheumatism</i> , 2003, 48, 35-45.	6.7	1,612
187	Development of a new instrument for rheumatoid arthritis: The Cedars-Sinai Health-Related Quality of Life instrument (CSHQ-RA). <i>Arthritis and Rheumatism</i> , 2003, 49, 78-84.	6.7	9
188	Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor- α monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study. <i>Clinical Therapeutics</i> , 2003, 25, 1700-1721.	2.5	279
189	What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. <i>Journal of rheumatology Supplement</i> , The, 2002, 65, 33-8.	2.2	65
190	Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2000, 343, 1594-1602.	27.0	2,910
191	Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: A randomized, double-blind six-week trial with eighteen-week extension. <i>Arthritis and Rheumatism</i> , 1999, 42, 357-365.	6.7	78
192	High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial. <i>Arthritis and Rheumatism</i> , 1999, 42, 1194-1203.	6.7	312
193	Correlates of the disability index of the health assessment questionnaire: A measure of functional impairment in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1999, 42, 2372-2380.	6.7	96
194	Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. <i>Lancet</i> , The, 1999, 354, 1932-1939.	13.7	2,266
195	Quality-adjusted life years lost to arthritis: Effects of gender, race, and social class. <i>Arthritis and Rheumatism</i> , 1996, 9, 473-482.	6.7	48
196	Primary lymphoma of the calcaneus. <i>Skeletal Radiology</i> , 1996, 25, 775-778.	2.0	18
197	Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A department of veterans affairs cooperative study. <i>Arthritis and Rheumatism</i> , 1996, 39, 2013-2020.	6.7	410
198	Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. <i>Arthritis and Rheumatism</i> , 1992, 35, 259-269.	6.7	139

#	ARTICLE	IF	CITATIONS
199	Reversible cause of back pain and sciatica in rheumatoid arthritis: An apophyseal joint cyst. Arthritis and Rheumatism, 1986, 29, 431-435.	6.7	31
200	Methotrexate pharmacokinetics after intraarticular injection in patients with rheumatoid arthritis. Arthritis and Rheumatism, 1980, 23, 119-122.	6.7	73
201	Manure shoveler's hip: A previously unrecognized syndrome. Arthritis and Rheumatism, 1979, 22, 940-941.	6.7	3